ASAHI KASEI PHARMA CORPORATION
Virtual Evening Symposium – Evolution of interleukin-6 inhibiting therapies for rheumatoid arthritis
Sunday 25 October – 5:40pm – 6:40pm
Check out the evening symposium!
Asahi Kasei Pharma discovers, develops, manufactures, and delivers prescription drugs in the fields of orthopedics, circulatory, urology,
the immune system, and the central nervous system. Pharmaceuticals from Asahi Kasei Pharma include Teribone™ for osteoporosis and Elcitonin™ Injection 20S for osteoporosis pain, the Recomodulin™ anticoagulant, each of which has a competitive position in its respective market.
Kevzara® is a human monoclonal antibody that blocks the action of interleukin-6 (IL-6) by binding to IL-6 receptors, for the indication of rheumatoid arthritis in patients who have had an inadequate response to conventional treatments.
Kevzara® is a registered trademark of Sanofi Biotechnology.
The product information is intended for general information purposes. The names, descriptions, and labeling of approved products are of Japan origin.
Product availability, names, indications, and presentations may vary from country to country.